Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's
disease (CD), is characterized by relapse and remission alternately. It remains a great …

Drugs available for asthma treatment in the first decades of the 20th century
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …

Endoscopy remains the reference standard for the diagnosis and assessment of patients
with inflammatory bowel disease (IBD), but it has several important limitations. Cross …

Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and
prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing …

Gastroenterologists will be all too familiar with the difficult decisions that managing
inflammatory bowel disease often presents. How aggressively should I treat this patient? Do …

Background & Aims Endoscopic and histologic remission have emerged as key therapeutic
goals in the management of inflammatory bowel diseases (IBD) that are associated with …

Short-and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during
the last decade, shifting from symptom control to endoscopic healing and patient-centered …

Objective IBD therapies and treatments are evolving to deeper levels of remission.
Molecular measures of disease may augment current endpoints including the potential for …

Background With the introduction of novel therapies for inflammatory bowel diseases
(IBD),'treat‐to‐target'strategies are increasingly discussed to improve short‐and long‐term …

Despite huge advances in understanding the molecular basis of IBD, clinical management
has continued to rely on a “trial and error” approach. In addition, a therapeutic ceiling has …